Yüksel Ürün: Trimodality therapy to offer hope for recurrent T1 bladder cancer after BCG failure
Yüksel Ürün, Medical Oncology Professor at Ankara University School of Medicine, shared a post on X:
“Trimodality therapy offers hope for recurrent T1 bladder cancer after BCG failure!
– 3-year freedom from cystectomy: 88%
– 3-year OS: 69%
– Distant metastasis at 3 years: 12%
An alternative to radical cystectomy, but safety monitoring is key.”
Authors: Douglas M. Dahl, Joseph P. Rodgers, William U. Shipley, M. Dror Michaelson, Chin-Lee Wu, William Parker, Ashesh B. Jani, Fabio L. Cury, Richard S. Hudes, Jeff M. Michalski, Alan C. Hartford, Daniel Song, Deborah E. Citrin, Theodore G. Karrison, Howard M. Sandler, Felix Y. Feng, Jason A. Efstathiou
More posts featuring Yüksel Ürün.
Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023